Spero Therapeutics SPRO
NASDAQ SPRO
$1.11 -0.02 (-1.78%)
As of: Oct 23, 2026 · 2:30 PM EDT

Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017)

Updated

Spero Therapeutics (SPRO) posted Income from Non-Controlling Interests of -$6,000 for Q4 2017, compared with -$986,000 a year earlier.

Analysis

Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017) Analysis & Trends

For FY2017, Spero Therapeutics' Income from Non-Controlling Interests came in at -$1.14 million.

  • In prior years, Spero Therapeutics' Income from Non-Controlling Interests was -$7.15 million in FY2016 and -$3 million in FY2015.
  • According to Business Quant data, Income from Non-Controlling Interests for the three prior quarters was -$8,000 (Q3 2017), -$594,000 (Q2 2017) and -$535,000 (Q1 2017).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,128.85 Bn 1,097.43 Bn 19.71 Bn -
2 Johnson & Johnson 634.21 Bn 554.07 Bn 17.30 Bn -
3 AbbVie 505.78 Bn 478.89 Bn 12.70 Bn 3.00 Mn
4 Merck 357.64 Bn 312.02 Bn 12.21 Bn -2.00 Mn
5 Novartis Ag 290.31 Bn 254.30 Bn 11.24 Bn -7.00 Mn
6 Astrazeneca 265.38 Bn 239.06 Bn 12.86 Bn 1.00 Mn
7 Amgen 238.11 Bn 193.51 Bn 7.24 Bn -
8 Gilead Sciences 194.79 Bn 168.99 Bn 6.22 Bn -
9 Pfizer 171.11 Bn 117.76 Bn 10.94 Bn 10.00 Mn
10 Spero Therapeutics 64.34 Mn -131.44 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 -6,000.00
Sep 30, 2017 -8,000.00
Jun 30, 2017 -594,000.00
Mar 31, 2017 -535,000.00
Dec 31, 2016 -986,000.00
Sep 30, 2016 -1.60 Mn
API Access

Spero Therapeutics Income from Non-Controlling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=SPRO&period=max&api_key=YOUR_API_KEY